Stay Ahead with Daily Biotech & HealthTech Innovation Insights
- by Associated PressPresident Trump is promising more payments to voters just ahead of the Nov. 3 midterm elections — this time for seniors' Medicare Part B premiums
- by Megan MolteniThe redesign is intended to streamline what was a sprawling and fractured information ecosystem, requiring users to understand NIH's organizational structure
- by Annalisa MerelliAhead of this year's Nobel Prize announcements, STAT chatted with Mary-Claire King, who discovered the BRCA cancer mutations and is frequently mentioned in prize predictions.
- by Theresa GaffneyOnly a small fraction of young people with opioid use disorder receive addiction medications, and few stay on them for long, a study finds.
- by Associated PressCongo's Ebola outbreak has killed more than 4,000 people, authorities said, as they struggle to contain what has become the fastest-growing Ebola outbreak in history.
- by Meghana KeshavanEli Lilly is launching LillyDirect to deliver Mounjaro straight to Australian patients’ doors — and local doctors and pharmacists aren’t thrilled.
- by Ed SilvermanFrom new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
- by Ed SilvermanThe U.S. approved 10 drugmakers to participate in a 340B pilot program that will allow them to offer rebates, instead of upfront discounts, to certain providers
- by Sarah Todd, Helen Branswell,and O. Rose BroderickNews of a fifth measles death in Pennsylvania underscores a longstanding issue about the disease. The full scope of the outbreak — in the state and in the country —…
- by Anil Oza, Jonathan Wosen,and J. Emory ParkerThe NIH continued reducing grants involving health disparities, race, and ethnicity but made little progress toward other administration priorities in the 2026 fiscal year.
- by Vibhu KrishnaA doctor’s request to marathons: Let’s make evidence-based medical plans — especially for extreme heat.
- by John MildenbergerThe law has to catch up on the 340B drug discount program, writes a pharmacist.
- by Bob HermanPremiums are stable, but Medicare Advantage plans are making big changes that could make care more expensive for patients.
- by Annalisa Merelli"Highlighting a ton of open questions": Top journal's special issue on women's health examines the latest discoveries on chronic pain and menopause.
- by Adam Feuerstein, Elaine Chen,and Allison DeAngelisWhy have so many Americans lost trust in science? And what's the deal with a new gene-editing lawsuit? Find out on this week's episode of "The Readout LOUD" podcast.
- by O. Rose BroderickProposed changes to the federal government’s health survey would undercount Americans with disabilities, advocates say.
- by Meghana KeshavanChinese-designed drugs now account for roughly half the global pipeline. STAT's Jason Mast traveled to Shanghai to get an up-close look at the competition that's making American's nervous.
- by John WilkersonHealth care companies dominate the MAHA Summit, and a look at Trump's watered down effort to lower Medicare drug prices.
- by Mario AguilarIn this edition of STAT Health Tech: A California insurer on how it may replicate Medicare's tech-enabled chronic-care experiment.
- by Ed SilvermanA final Medicare rule aimed at lowering prices for doctor-administered drugs applies to only four companies and saves 96% less than the initial proposal
RSS Error: Retrieved unsupported status code "403"
- by Frank VinluanWhile the immune reset field is mainly focused on depleting pathogenic B cells, ai3Bio is applying its novel approach to inflammatory T cells. The startup’s initial disease targets are autoimmune disorders of the liver that have few treatment options if any at all. The post Immunology Startup ai3Bio Aims to Redefine What It Means to Reset the Immune System appeared first on MedCity News.
- by Marissa PlesciaThe Trump administration’s ACA fraud crackdown will remove 760,000 people from Marketplace coverage, drawing criticism from healthcare experts and advocates. The post Trump’s ACA Fraud Crackdown: Experts Urge Going After Bad Actors, Not Patients appeared first on MedCity News.
- by Gary FalcetanoRural patients, Medicaid enrollees, and patients from underrepresented racial and ethnic groups are more likely to go undiagnosed, more likely to be misdiagnosed, and more likely to end up in an emergency department rather than an allergist’s office. The post Closing the Diagnostic Gap: Why Access to Allergy Care Isn’t Equal appeared first on MedCity News.
- by Jenna CongdonAt a recent symposium on privacy, experts discussed how AI supports a faster and oftentimes more insightful approach to data security, while identifying which privacy risks healthcare organizations must monitor. The post Healthcare Privacy Leaders Look to AI to Improve Monitoring and Data Breach Investigations appeared first on MedCity News.
- by Stephanie BaumDebunked Podcast co-hosts Arundhati Parmar and Samir Batra discussed the merits of the CMS ACCESS Model (Advancing Chronic Care with Effective, Scalable Solutions) and how it can offer a path to advance value-based care goals. The post Debunked Episode 30: ACCESS Tries to Succeed Where VBC Fails, AI, and UnitedHealth Gets the Last Week Tonight Treatment appeared first on MedCity News.
- by Marissa PlesciaThe Series A round was led by Canvas Ventures, with participation from Blank Space Ventures, StoryHouse Ventures and HMC INQ. The post Parakeet Health Secures $10M for Conversational Agentic Platform appeared first on MedCity News.
- by Frank VinluanPfizer’s Litfulo significantly improved skin pigment measures in two pivotal studies in vitiligo, results that were presented during the European Academy of Dermatology and Venereology annual meeting. If Pfizer’s daily pill is approved, it would compete against an Incyte topical cream that is currently the only FDA-approved therapy for this autoimmune skin disorder. The post Pfizer Pill’s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions appeared first on MedCity News.
- by Lisa MillerData, behavioral insights, and experimentation can be used to understand how stress, motivation, and trust shape company culture. Positively changing company culture leads to direct improvements in patient health outcomes, clinician wellbeing, and company performance. The post It’s Time We Reframe Healthcare Organizational Culture Using Behavioral Science appeared first on MedCity News.
- by wlim[Sponsored] In this webinar pharmacy leaders share how hospitals are using stewardship as a sustainability strategy to control costs and ease the load on pharmacists. The post Hospitals’ Cost Containment Conundrum appeared first on MedCity News.
- by Marissa PlesciaThe AMA found that OptumRx, Express Scripts, CVS Caremark and Prime Therapeutics controlled 75% of the national PBM market in 2024. The post AMA: PBM Market Concentration Is On the Rise appeared first on MedCity News.
- by Frank VinluanSanofi and Regeneron Pharmaceuticals will collaborate on four next-generation antibody drugs that could offer advantages over Dupixent, the blockbuster immunology drug spawned by their R&D alliance. The companies project these drugs will start reaching pivotal testing in 2029 — important because Dupixent faces patent expiration in 2031. The post Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent appeared first on MedCity News.
- by Adam CohenWhy more than 300,000 missing patient records reveal an engineering problem, not a policy one — and why that’s good news. The post The Real Gap in All of Us Isn’t Consent, It’s Conversion appeared first on MedCity News.
- by Frank VinluanThe FDA is recruiting to fill vacancies on its advisory committees, informally known as adcomms. While these committees have met less frequently during the Trump administration, more meetings have been scheduled since former Commissioner Marty Makary left the agency in May. The post FDA Looks to Bring New Scientific, Consumer Voices to Advisory Committees appeared first on MedCity News.
- by Marissa PlesciaIn this episode, we’re joined by Claire Love, PwC’s global health industries advisory leader. We discuss PwC’s recent report showing the opportunities in the fertility and reproductive health market. The post MedCity FemFwd: Opportunities in the Fertility Market appeared first on MedCity News.
- by Marissa PlesciaHealth tech companies made several major funding announcements in September. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in September appeared first on MedCity News.
- by Jenna CongdonFor one ICU physician and startup CMO, the more immediate danger isn’t an autonomous system taking over medicine and leaving human decision-making behind. It’s healthcare organizations harnessing AI primarily to increase efficiency while leaving healthcare providers even more mired in complexity and regulation. The post AI’s Healthcare ‘Doomsday’? It May Be Less About Autonomy Than Trust appeared first on MedCity News.
- by Mark TaylorAI could play a meaningful role in advancing social care. Not by replacing people, but by helping them and organizations doing this work move faster, see patterns earlier, and coordinate more effectively. The post AI Won’t Fix Social Care, But Could It Help Us Finally Make It Work? appeared first on MedCity News.
- by Marissa PlesciaTiny Health’s Series B round was led by B Capital, with participation from Spero Ventures, The Venture City, Overwater Ventures, Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures. The post Tiny Health Secures $33M to Expand Microbiome Testing appeared first on MedCity News.
- by Jenna CongdonUnite Us and Instacart announced Tuesday that they are partnering to connect healthcare organizations’ care coordination efforts with grocery benefits, with the aim of making food-as-medicine programs easier to launch and operate at scale. The post Unite Us, Instacart Link Care Coordination and Grocery Benefits to Scale Food-as-Medicine appeared first on MedCity News.
- by Frank VinluanAstraZeneca’s equity investment in Summit Therapeutics comes with plans for clinical trial collaborations. The deal brings AstraZeneca into a growing group of pharmaceutical companies testing the pairing of antibody drug conjugates with PD-1/VEGF bispecific antibodies, a drug combination that could offer advantages in cancer treatment. The post AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug appeared first on MedCity News.